Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36

John F Carlquist1, Joseph B Muhlestein, Benjamin D Horne

  • 1Cardiovascular Department, LDS Hospital, 8th Avenue and C Street, Salt Lake City, UT 84143, USA. john.carlquist@ihc.com

Atherosclerosis
|October 19, 2004
PubMed
Abstract

Insights

Cytomegalovirus (CMV) infection increases CD36 expression in macrophages, a key receptor for oxidized LDL. This CMV-induced CD36 upregulation may contribute to atherosclerosis development.

Area of Science:

  • Immunology
  • Cardiovascular Biology
  • Virology

Background:

  • Cytomegalovirus (CMV) is epidemiologically linked to atherosclerosis, including coronary, carotid, and cardiac graft disease.
  • Macrophage uptake of oxidized low-density lipoproteins (OxLDL) via the scavenger receptor CD36 is an early event in atherogenesis.
  • CMV's ability to activate host-cell gene transcription suggests a potential role in modulating atherogenic pathways.

Purpose of the Study:

  • To investigate the hypothesis that CMV infection upregulates CD36 expression in macrophages.
  • To determine if CMV-induced CD36 expression contributes to the uptake of OxLDL, a critical step in atherosclerosis.

Main Methods:

  • THP-1 monocyte/macrophage cells were infected with Davis strain CMV.
  • Cell surface CD36 expression and mRNA levels were quantified using flow cytometry and RT-PCR.
  • The role of the p38 mitogen-activated protein kinase pathway was assessed using a specific inhibitor (SB203580).
  • Oxidized LDL uptake was evaluated microscopically.

Main Results:

  • CMV infection significantly increased the percentage of cells expressing CD36 and CD36 mRNA levels.
  • Viral challenge upregulated p38 MAPK, and its inhibition reversed CMV-induced CD36 expression.
  • CMV-treated cells exhibited increased uptake of OxLDL.

Conclusions:

  • CMV-induced CD36 expression represents a potential mechanism by which CMV promotes atherosclerosis.
  • Further research is needed to explore other CMV-associated atherogenic mechanisms.